Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Mateon Therapeutics (OTCMKTS:MATN) Head to Head Survey

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Mateon Therapeutics (OTCMKTS:MATN) are both small-cap manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Earnings and Valuation

This table compares Cyclacel Pharmaceuticals and Mateon Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$40,000.00	161.70	-$11.21 million	($81.45)	-0.02
Mateon Therapeutics	N/A	N/A	-$6.64 million	($0.02)	-3.61

Mateon Therapeutics has lower revenue, but higher earnings than Cyclacel Pharmaceuticals. Mateon Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Cyclacel Pharmaceuticals has a beta of -0.45, indicating that its share price is 145% less volatile than the S&P 500. Comparatively, Mateon Therapeutics has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Profitability

This table compares Cyclacel Pharmaceuticals and Mateon Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-187.37%	-106.68%
Mateon Therapeutics	N/A	-64.66%	-42.92%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Cyclacel Pharmaceuticals and Mateon Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1	0	0	0	1.00
Mateon Therapeutics	0	0	0	0	0.00

Institutional & Insider Ownership

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Mateon Therapeutics shares are held by institutional investors. 51.2% of Cyclacel Pharmaceuticals shares are held by insiders. Comparatively, 39.2% of Mateon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing’s disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.